---
title: 'üî¨Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery'
description: 'the next frontier lies in modeling complex interactions and generative protein design This podcast features **[Gabriele Corso](https://www.linkedin.co'
icon: 'newspaper'
author: 'Swyx'
authorId: 'swyx'
published: '2026-02-12'
sourceUrl: 'https://www.latent.space/p/boltz'
topics: ["Generative Protein Design","Open Source","Structural Biology","Drug Discovery"]
diataxisType: 'explanation'
---

<Info>
**Original**: [Swyx](https://www.latent.space/p/boltz) ¬∑ 12/02/2026
</Info>

## Summary

the next frontier lies in modeling complex interactions and generative protein design This podcast features **[Gabriele Corso](https://www.linkedin.com/in/gcorso/) and [Jeremy Wohlwend](https://jeremywohlwend.com/)**, co-founders of **Boltz** and authors of **[the Boltz Manifesto](https://www.a16z.news/p/science-at-the-speed-of-inference)**, discussing the rapid evolution of structur

## Key Insights

> "the next frontier lies in modeling complex interactions and generative protein design"
>
> ‚Äî Discussing the evolution of structural biology models and Boltz's focus.

> "Boltz-1 was moving from regression to a generative diffusion approach"
>
> ‚Äî Explaining the shift in model architecture from static prediction to generative models.

> "Boltz Lab platform provides 'agents' for protein and small molecule design"
>
> ‚Äî Introducing the Boltz Lab infrastructure for faster and more efficient drug design.

## Topics

- [Generative Protein Design](/kb/topics/generative-protein-design)
- [Open Source](/kb/topics/open-source)
- [Structural Biology](/kb/topics/structural-biology)
- [Drug Discovery](/kb/topics/drug-discovery)

---

## Full Article

```
# üî¨Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery
```

**Author**: Swyx  
**Published**: 2026-02-12  
**Source**: [https://www.latent.space/p/boltz](https://www.latent.space/p/boltz)

---

This podcast features **[Gabriele Corso](https://www.linkedin.com/in/gcorso/) and [Jeremy Wohlwend](https://jeremywohlwend.com/)**, co-founders of **Boltz** and authors of **[the Boltz Manifesto](https://www.a16z.news/p/science-at-the-speed-of-inference)**, discussing the rapid evolution of structural biology models from **AlphaFold** to their own open-source suite, **Boltz-1** and **Boltz-2**. The central thesis is that while single-chain protein structure prediction is largely ‚Äúsolved‚Äù through evolutionary hints, the next frontier lies in **modeling complex interactions** (protein-ligand, protein-protein) and **generative protein design**, which Boltz aims to democratize via open-source foundations and scalable infrastructure.

## Full Video Pod

On [YouTube](https://www.youtube.com/watch?v=nP0N1kYLegc)!

## Timestamps

```
* 00:00 Introduction to Benchmarking and the ‚ÄúSolved‚Äù Protein Problem
* 06:48 Evolutionary Hints and Co-evolution in Structure Prediction
* 10:00 The Importance of Protein Function and Disease States
* 15:31 Transitioning from AlphaFold 2 to AlphaFold 3 Capabilities
* 19:48 Generative Modeling vs. Regression in Structural Biology
* 25:00 The ‚ÄúBitter Lesson‚Äù and Specialized AI Architectures
* 29:14 Development Anecdotes: Training Boltz-1 on a Budget
* 32:00 Validation Strategies and the Protein Data Bank (PDB)
* 37:26 The Mission of Boltz: Democratizing Access and Open Source
* 41:43 Building a Self-Sustaining Research Community
* 44:40 Boltz-2 Advancements: Affinity Prediction and Design
* 51:03 BoltzGen: Merging Structure and Sequence Prediction
* 55:18 Large-Scale Wet Lab Validation Results
* 01:02:44 Boltz Lab Product Launch: Agents and Infrastructure
* 01:13:06 Future Directions: Developpability and the ‚ÄúVirtual Cell‚Äù
* 01:17:35 Interacting with Skeptical Medicinal Chemists
```

---

## Key Summary

### Evolution of Structure Prediction & Evolutionary Hints

```
* **Co-evolutionary Landscapes**: The speakers explain that breakthrough progress in single-chain protein prediction relied on decoding evolutionary correlations where mutations in one position necessitate mutations in another to conserve 3D structure.
* **Structure vs. Folding**: They differentiate between **structure prediction** (getting the final answer) and **folding** (the kinetic process of reaching that state), noting that the field is still quite poor at modeling the latter.
* **Physics vs. Statistics**: RJ posits that while models use evolutionary statistics to find the right ‚Äúvalley‚Äù in the energy landscape, they likely possess a ‚Äúlight understanding‚Äù of physics to refine the local minimum.
```

### The Shift to Generative Architectures

```
* **Generative Modeling**: A key leap in **AlphaFold 3** and **Boltz-1** was moving from regression (predicting one static coordinate) to a **generative diffusion** approach that samples from a posterior distribution.
* **Handling Uncertainty**: This shift allows models to represent multiple conformational states and avoid the ‚Äúaveraging‚Äù effect seen in regression models when the ground truth is ambiguous.
* **Specialized Architectures**: Despite the ‚Äúbitter lesson‚Äù of general-purpose transformers, the speakers argue that **equivariant architectures** remain vastly superior for biological data due to the inherent 3D geometric constraints of molecules.
```

### Boltz-2 and Generative Protein Design

```
* **Unified Encoding**: **Boltz-2** (and BoltzGen) treats structure and sequence prediction as a single task by encoding amino acid identities into the atomic composition of the predicted structure.
* **Design Specifics**: Instead of a sequence, users feed the model **blank tokens** and a high-level ‚Äúspec‚Äù (e.g., an antibody framework), and the model decodes both the 3D structure and the corresponding amino acids.
* **Affinity Prediction**: While model **confidence** is a common metric, Boltz-2 focuses on **affinity prediction**‚Äîquantifying exactly how tightly a designed binder will stick to its target.
```

### Real-World Validation and Productization

```
* **Generalized Validation**: To prove the model isn‚Äôt just ‚Äúregurgitating‚Äù known data, Boltz tested its designs on 9 targets with **zero known interactions** in the PDB, achieving **nanomolar binders** for two-thirds of them.
* **Boltz Lab Infrastructure**: The newly launched **Boltz Lab** platform provides ‚Äúagents‚Äù for protein and small molecule design, optimized to run 10x faster than open-source versions through proprietary GPU kernels.
* **Human-in-the-Loop**: The platform is designed to convert skeptical **medicinal chemists** by allowing them to run parallel screens and use their intuition to filter model outputs.
```

---

## Transcript

**RJ** [00:05:35]: But the goal remains to, like, you know, really challenge the models, like, how well do these models generalize? And, you know, we‚Äôve seen in some of the latest CASP competitions, like, while we‚Äôve become really, really good at proteins, especially monomeric proteins, you know, other modalities still remain pretty difficult. So it‚Äôs really essential, you know, in the field that there are, like, these efforts to gather, you know, benchmarks that are challenging. So it keeps us in line, you know, about what the models can do or not.

**Gabriel** [00:06:26]: Yeah, it‚Äôs interesting you say that, like, in some sense, CASP, you know, at CASP 14, a problem was solved and, like, pretty comprehensively, right? But at the same time, it was really only the beginning. So you can say, like, what was the specific problem you would argue was solved? And then, like, you know, what is remaining, which is probably quite open.

**RJ** [00:06:48]: I think we‚Äôll steer away from the term solved, because we have many friends in the community who get pretty upset at that word. And I think, you know, fairly so. But the problem that was, you know, that a lot of progress was made on was the ability to predict the structure of single chain proteins. So proteins can, like, be composed of many chains. And single chain proteins are, you know, just a single sequence of amino acids. And one of the reasons that we‚Äôve been able to make such progress is also because we take a lot of hints from evolution. So the way the models work is that, you know, they sort of decode a lot of hints. That comes from evolutionary landscapes. So if you have, like, you know, some protein in an animal, and you go find the similar protein across, like, you know, different organisms, you might find different mutations in them. And as it turns out, if you take a lot of the sequences together, and you analyze them, you see that some positions in the sequence tend to evolve at the same time as other positions in the sequence, sort of this, like, correlation between different positions. And it turns out that that is typically a hint that these two positions are close in three dimension. So part of the, you know, part of the breakthrough has been, like, our ability to also decode that very, very effectively. But what it implies also is that in absence of that co-evolutionary landscape, the models don‚Äôt quite perform as well. And so, you know, I think when that information is available, maybe one could say, you know, the problem is, like, somewhat solved. From the perspective of structure prediction, when it isn‚Äôt, it‚Äôs much more challenging. And I think it‚Äôs also worth also differentiating the, sometimes we confound a little bit, structure prediction and folding. Folding is the more complex process of actually understanding, like, how it goes from, like, this disordered state into, like, a structured, like, state. And that I don‚Äôt think we‚Äôve made that much progress on. But the idea of, like, yeah, going straight to the answer, we‚Äôve become pretty good at.

**Brandon** [00:08:49]: So there‚Äôs this protein that is, like, just a long chain and it folds up. Yeah. And so we‚Äôre good at getting from that long chain in whatever form it was originally to the thing. But we don‚Äôt know how it necessarily gets to that state. And there might be intermediate states that it‚Äôs in sometimes that we‚Äôre not aware of.

**RJ** [00:09:10]: That‚Äôs right. And that relates also to, like, you know, our general ability to model, like, the different, you know, proteins are not static. They move, they take different shapes based on their energy states. And I think we are, also not that good at understanding the different states that the protein can be in and at what frequency, what probability. So I think the two problems are quite related in some ways. Still a lot to solve. But I think it was very surprising at the time, you know, that even with these evolutionary hints that we were able to, you know, to make such dramatic progress.

**Brandon** [00:09:45]: So I want to ask, why does the intermediate states matter? But first, I kind of want to understand, why do we care? What proteins are shaped like?

**Gabriel** [00:09:54]: Yeah, I mean, the proteins are kind of the machines of our body. You know, the way that all the processes that we have in our cells, you know, work is typically through proteins, sometimes other molecules, sort of intermediate interactions. And through that interactions, we have all sorts of cell functions. And so when we try to understand, you know, a lot of biology, how our body works, how disease work. So we often try to boil it down to, okay, what is going right in case of, you know, our normal biological function and what is going wrong in case of the disease state. And we boil it down to kind of, you know, proteins and kind of other molecules and their interaction. And so when we try predicting the structure of proteins, it‚Äôs critical to, you know, have an understanding of kind of those interactions. It‚Äôs a bit like seeing the difference between... Having kind of a list of parts that you would put it in a car and seeing kind of the car in its final form, you know, seeing the car really helps you understand what it does. On the other hand, kind of going to your question of, you know, why do we care about, you know, how the protein falls or, you know, how the car is made to some extent is that, you know, sometimes when something goes wrong, you know, there are, you know, cases of, you know, proteins misfolding. In some diseases and so on, if we don‚Äôt understand this folding process, we don‚Äôt really know how to intervene.

**RJ** [00:11:30]: There‚Äôs this nice line in the, I think it‚Äôs in the Alpha Fold 2 manuscript, where they sort of discuss also like why we even hopeful that we can target the problem in the first place. And then there‚Äôs this notion that like, well, four proteins that fold. The folding process is almost instantaneous, which is a strong, like, you know, signal that like, yeah, like we should, we might be... able to predict that this very like constrained thing that, that the protein does so quickly. And of course that‚Äôs not the case for, you know, for, for all proteins. And there‚Äôs a lot of like really interesting mechanisms in the cells, but yeah, I remember reading that and thought, yeah, that‚Äôs somewhat of an insightful point.

**Gabriel** [00:12:10]: I think one of the interesting things about the protein folding problem is that it used to be actually studied. And part of the reason why people thought it was impossible, it used to be studied as kind of like a classical example. Of like an MP problem. Uh, like there are so many different, you know, type of, you know, shapes that, you know, this amino acid could take. And so, this grows combinatorially with the size of the sequence. And so there used to be kind of a lot of actually kind of more theoretical computer science thinking about and studying protein folding as an MP problem. And so it was very surprising also from that perspective, kind of seeing. Machine learning so clear, there is some, you know, signal in those sequences, through evolution, but also through kind of other things that, you know, us as humans, we‚Äôre probably not really able to, uh, to understand, but that is, models I‚Äôve, I‚Äôve learned.

**Brandon** [00:13:07]: And so Andrew White, we were talking to him a few weeks ago and he said that he was following the development of this and that there were actually ASICs that were developed just to solve this problem. So, again, that there were. There were many, many, many millions of computational hours spent trying to solve this problem before AlphaFold. And just to be clear, one thing that you mentioned was that there‚Äôs this kind of co-evolution of mutations and that you see this again and again in different species. So explain why does that give us a good hint that they‚Äôre close by to each other? Yeah.

**RJ** [00:13:41]: Um, like think of it this way that, you know, if I have, you know, some amino acid that mutates, it‚Äôs going to impact everything around it. Right. In three dimensions. And so it‚Äôs almost like the protein through several, probably random mutations and evolution, like, you know, ends up sort of figuring out that this other amino acid needs to change as well for the structure to be conserved. Uh, so this whole principle is that the structure is probably largely conserved, you know, because there‚Äôs this function associated with it. And so it‚Äôs really sort of like different positions compensating for, for each other. I see.

**Brandon** [00:14:17]: Those hints in aggregate give us a lot. Yeah. So you can start to look at what kinds of information about what is close to each other, and then you can start to look at what kinds of folds are possible given the structure and then what is the end state.

**RJ** [00:14:30]: And therefore you can make a lot of inferences about what the actual total shape is. Yeah, that‚Äôs right. It‚Äôs almost like, you know, you have this big, like three dimensional Valley, you know, where you‚Äôre sort of trying to find like these like low energy states and there‚Äôs so much to search through. That‚Äôs almost overwhelming. But these hints, they sort of maybe put you in. An area of the space that‚Äôs already like, kind of close to the solution, maybe not quite there yet. And, and there‚Äôs always this question of like, how much physics are these models learning, you know, versus like, just pure like statistics. And like, I think one of the thing, at least I believe is that once you‚Äôre in that sort of approximate area of the solution space, then the models have like some understanding, you know, of how to get you to like, you know, the lower energy, uh, low energy state. And so maybe you have some, some light understanding. Of physics, but maybe not quite enough, you know, to know how to like navigate the whole space. Right. Okay.

**Brandon** [00:15:25]: So we need to give it these hints to kind of get into the right Valley and then it finds the, the minimum or something. Yeah.

**Gabriel** [00:15:31]: One interesting explanation about our awful free works that I think it‚Äôs quite insightful, of course, doesn‚Äôt cover kind of the entirety of, of what awful does that is, um, they‚Äôre going to borrow from, uh, Sergio Chinico for MIT. So he sees kind of awful. Then the interesting thing about awful is God. This very peculiar architecture that we have seen, you know, used, and this architecture operates on this, you know, pairwise context between amino acids. And so the idea is that probably the MSA gives you this first hint about what potential amino acids are close to each other. MSA is most multiple sequence alignment. Exactly. Yeah. Exactly. This evolutionary information. Yeah. And, you know, from this evolutionary information about potential contacts, then is almost as if the model is. of running some kind of, you know, diastro algorithm where it‚Äôs sort of decoding, okay, these have to be closed. Okay. Then if these are closed and this is connected to this, then this has to be somewhat closed. And so you decode this, that becomes basically a pairwise kind of distance matrix. And then from this rough pairwise distance matrix, you decode kind of the

**Brandon** [00:16:42]: actual potential structure. Interesting. So there‚Äôs kind of two different things going on in the kind of coarse grain and then the fine grain optimizations. Interesting. Yeah. Very cool.

**Gabriel** [00:16:53]: Yeah. You mentioned AlphaFold3. So maybe we have a good time to move on to that. So yeah, AlphaFold2 came out and it was like, I think fairly groundbreaking for this field. Everyone got very excited. A few years later, AlphaFold3 came out and maybe for some more history, like what were the advancements in AlphaFold3? And then I think maybe we‚Äôll, after that, we‚Äôll talk a bit about the sort of how it connects to Bolt. But anyway. Yeah. So after AlphaFold2 came out, you know, Jeremy and I got into the field and with many others, you know, the clear problem that, you know, was, you know, obvious after that was, okay, now we can do individual chains. Can we do interactions, interaction, different proteins, proteins with small molecules, proteins with other molecules. And so. So why are interactions important? Interactions are important because to some extent that‚Äôs kind of the way that, you know, these machines, you know, these proteins have a function, you know, the function comes by the way that they interact with other proteins and other molecules. Actually, in the first place, you know, the individual machines are often, as Jeremy was mentioning, not made of a single chain, but they‚Äôre made of the multiple chains. And then these multiple chains interact with other molecules to give the function to those. And on the other hand, you know, when we try to intervene of these interactions, think about like a disease, think about like a, a biosensor or many other ways we are trying to design the molecules or proteins that interact in a particular way with what we would call a target protein or target. You know, this problem after AlphaVol2, you know, became clear, kind of one of the biggest problems in the field to, to solve many groups, including kind of ours and others, you know, started making some kind of contributions to this problem of trying to model these interactions. And AlphaVol3 was, you know, was a significant advancement on the problem of modeling interactions. And one of the interesting thing that they were able to do while, you know, some of the rest of the field that really tried to try to model different interactions separately, you know, how protein interacts with small molecules, how protein interacts with other proteins, how RNA or DNA have their structure, they put everything together and, you know, train very large models with a lot of advances, including kind of changing kind of systems. Some of the key architectural choices and managed to get a single model that was able to set this new state-of-the-art performance across all of these different kind of modalities, whether that was protein, small molecules is critical to developing kind of new drugs, protein, protein, understanding, you know, interactions of, you know, proteins with RNA and DNAs and so on.

**Brandon** [00:19:39]: Just to satisfy the AI engineers in the audience, what were some of the key architectural and data, data changes that made that possible?

**Gabriel** [00:19:48]: Yeah, so one critical one that was not necessarily just unique to AlphaFold3, but there were actually a few other teams, including ours in the field that proposed this, was moving from, you know, modeling structure prediction as a regression problem. So where there is a single answer and you‚Äôre trying to shoot for that answer to a generative modeling problem where you have a posterior distribution of possible structures and you‚Äôre trying to sample this distribution. And this achieves two things. One is it starts to allow us to try to model more dynamic systems. As we said, you know, some of these structures can actually take multiple structures. And so, you know, you can now model that, you know, through kind of modeling the entire distribution. But on the second hand, from more kind of core modeling questions, when you move from a regression problem to a generative modeling problem, you are really tackling the way that you think about uncertainty in the model in a different way. So if you think about, you know, I‚Äôm undecided between different answers, what‚Äôs going to happen in a regression model is that, you know, I‚Äôm going to try to make an average of those different kind of answers that I had in mind. When you have a generative model, what you‚Äôre going to do is, you know, sample all these different answers and then maybe use separate models to analyze those different answers and pick out the best. So that was kind of one of the critical improvement. The other improvement is that they significantly simplified, to some extent, the architecture, especially of the final model that takes kind of those pairwise representations and turns them into an actual structure. And that now looks a lot more like a more traditional transformer than, you know, like a very specialized equivariant architecture that it was in AlphaFold3.

**Brandon** [00:21:41]: So this is a bitter lesson, a little bit.

**Gabriel** [00:21:45]: There is some aspect of a bitter lesson, but the interesting thing is that it‚Äôs very far from, you know, being like a simple transformer. This field is one of the, I argue, very few fields in applied machine learning where we still have kind of architecture that are very specialized. And, you know, there are many people that have tried to replace these architectures with, you know, simple transformers. And, you know, there is a lot of debate in the field, but I think kind of that most of the consensus is that, you know, the performance... that we get from the specialized architecture is vastly superior than what we get through a single transformer. Another interesting thing that I think on the staying on the modeling machine learning side, which I think it‚Äôs somewhat counterintuitive seeing some of the other kind of fields and applications is that scaling hasn‚Äôt really worked kind of the same in this field. Now, you know, models like AlphaFold2 and AlphaFold3 are, you know, still very large models.

**RJ** [00:29:14]: in a place, I think, where we had, you know, some experience working in, you know, with the data and working with this type of models. And I think that put us already in like a good place to, you know, to produce it quickly. And, you know, and I would even say, like, I think we could have done it quicker. The problem was like, for a while, we didn‚Äôt really have the compute. And so we couldn‚Äôt really train the model. And actually, we only trained the big model once. That‚Äôs how much compute we had. We could only train it once. And so like, while the model was training, we were like, finding bugs left and right. A lot of them that I wrote. And like, I remember like, I was like, sort of like, you know, doing like, surgery in the middle, like stopping the run, making the fix, like relaunching. And yeah, we never actually went back to the start. We just like kept training it with like the bug fixes along the way, which was impossible to reproduce now. Yeah, yeah, no, that model is like, has gone through such a curriculum that, you know, learned some weird stuff. But yeah, somehow by miracle, it worked out.

**Gabriel** [00:30:13]: The other funny thing is that the way that we were training, most of that model was through a cluster from the Department of Energy. But that‚Äôs sort of like a shared cluster that many groups use. And so we were basically training the model for two days, and then it would go back to the queue and stay a week in the queue. Oh, yeah. And so it was pretty painful. And so we actually kind of towards the end with Evan, the CEO of Genesis, and basically, you know, I was telling him a bit about the project and, you know, kind of telling him about this frustration with the compute. And so luckily, you know, he offered to kind of help. And so we, we got the help from Genesis to, you know, finish up the model. Otherwise, it probably would have taken a couple of extra weeks.

**Brandon** [00:30:57]: Yeah, yeah.

**Brandon** [00:31:02]: And then, and then there‚Äôs some progression from there.

**Gabriel** [00:31:06]: Yeah, so I would say kind of that, both one, but also kind of these other kind of set of models that came around the same time, were kind of approaching were a big leap from, you know, kind of the previous kind of open source models, and, you know, kind of really kind of approaching the level of AlphaVault 3. But I would still say that, you know, even to this day, there are, you know, some... specific instances where AlphaVault 3 works better. I think one common example is antibody antigen prediction, where, you know, AlphaVault 3 still seems to have an edge in many situations. Obviously, these are somewhat different models. They are, you know, you run them, you obtain different results. So it‚Äôs, it‚Äôs not always the case that one model is better than the other, but kind of in aggregate, we still, especially at the time.

**Brandon** [00:32:00]: So AlphaVault 3 is, you know, still having a bit of an edge. We should talk about this more when we talk about Boltzgen, but like, how do you know one is, one model is better than the other? Like you, so you, I make a prediction, you make a prediction, like, how do you know?

**Gabriel** [00:32:11]: Yeah, so easily, you know, the, the great thing about kind of structural prediction and, you know, once we‚Äôre going to go into the design space of designing new small molecule, new proteins, this becomes a lot more complex. But a great thing about structural prediction is that a bit like, you know, CASP was doing, basically the way that you can evaluate them is that, you know, you train... You know, you train a model on a structure that was, you know, released across the field up until a certain time. And, you know, one of the things that we didn‚Äôt talk about that was really critical in all this development is the PDB, which is the Protein Data Bank. It‚Äôs this common resources, basically common database where every biologist publishes their structures. And so we can, you know, train on, you know, all the structures that were put in the PDB until a certain date. And then... And then we basically look for recent structures, okay, which structures look pretty different from anything that was published before, because we really want to try to understand generalization.

**Brandon** [00:33:13]: And then on this new structure, we evaluate all these different models. And so you just know when AlphaFold3 was trained, you know, when you‚Äôre, you intentionally trained to the same date or something like that. Exactly. Right. Yeah.

**Gabriel** [00:33:24]: And so this is kind of the way that you can somewhat easily kind of compare these models, obviously, that assumes that, you know, the training. You‚Äôve always been very passionate about validation. I remember like DiffDoc, and then there was like DiffDocL and DocGen. You‚Äôve thought very carefully about this in the past. Like, actually, I think DocGen is like a really funny story that I think, I don‚Äôt know if you want to talk about that. It‚Äôs an interesting like... Yeah, I think one of the amazing things about putting things open source is that we get a ton of feedback from the field. And, you know, sometimes we get kind of great feedback of people. Really like... But honestly, most of the times, you know, to be honest, that‚Äôs also maybe the most useful feedback is, you know, people sharing about where it doesn‚Äôt work. And so, you know, at the end of the day, it‚Äôs critical. And this is also something, you know, across other fields of machine learning. It‚Äôs always critical to set, to do progress in machine learning, set clear benchmarks. And as, you know, you start doing progress of certain benchmarks, then, you know, you need to improve the benchmarks and make them harder and harder. And this is kind of the progression of, you know, how the field operates. And so, you know, the example of DocGen was, you know, we published this initial model called DiffDoc in my first year of PhD, which was sort of like, you know, one of the early models to try to predict kind of interactions between proteins, small molecules, that we bought a year after AlphaFold2 was published. And now, on the one hand, you know, on these benchmarks that we were using at the time, DiffDoc was doing really well, kind of, you know, outperforming kind of some of the traditional physics-based methods. But on the other hand, you know, when we started, you know, kind of giving these tools to kind of many biologists, and one example was that we collaborated with was the group of Nick Polizzi at Harvard. We noticed, started noticing that there was this clear, pattern where four proteins that were very different from the ones that we‚Äôre trained on, the models was, was struggling. And so, you know, that seemed clear that, you know, this is probably kind of where we should, you know, put our focus on. And so we first developed, you know, with Nick and his group, a new benchmark, and then, you know, went after and said, okay, what can we change? And kind of about the current architecture to improve this pattern and generalization. And this is the same that, you know, we‚Äôre still doing today, you know, kind of, where does the model not work, you know, and then, you know, once we have that benchmark, you know, let‚Äôs try to, through everything we, any ideas that we have of the problem.

**RJ** [00:36:15]: And there‚Äôs a lot of like healthy skepticism in the field, which I think, you know, is, is, is great. And I think, you know, it‚Äôs very clear that there‚Äôs a ton of things, the models don‚Äôt really work well on, but I think one thing that‚Äôs probably, you know, undeniable is just like the pace of, pace of progress, you know, and how, how much better we‚Äôre getting, you know, every year. And so I think if you, you know, if you assume, you know, any constant, you know, rate of progress moving forward, I think things are going to look pretty cool at some point in the future.

**Gabriel** [00:36:42]: ChatGPT was only three years ago. Yeah, I mean, it‚Äôs wild, right?

**RJ** [00:36:45]: Like, yeah, yeah, yeah, it‚Äôs one of those things. Like, you‚Äôve been doing this. Being in the field, you don‚Äôt see it coming, you know? And like, I think, yeah, hopefully we‚Äôll, you know, we‚Äôll, we‚Äôll continue to have as much progress we‚Äôve had the past few years.

**Brandon** [00:36:55]: So this is maybe an aside, but I‚Äôm really curious, you get this great feedback from the, from the community, right? By being open source. My question is partly like, okay, yeah, if you open source and everyone can copy what you did, but it‚Äôs also maybe balancing priorities, right? Where you, like all my customers are saying. I want this, there‚Äôs all these problems with the model. Yeah, yeah. But my customers don‚Äôt care, right? So like, how do you, how do you think about that? Yeah.

**Gabriel** [00:37:26]: So I would say a couple of things. One is, you know, part of our goal with Bolts and, you know, this is also kind of established as kind of the mission of the public benefit company that we started is to democratize the access to these tools. But one of the reasons why we realized that Bolts needed to be a company, it couldn‚Äôt just be an academic project is that putting a model on GitHub is definitely not enough to get, you know, chemists and biologists, you know, across, you know, both academia, biotech and pharma to use your model to, in their therapeutic programs. And so a lot of what we think about, you know, at Bolts beyond kind of the, just the models is thinking about all the layers. The layers that come on top of the models to get, you know, from, you know, those models to something that can really enable scientists in the industry. And so that goes, you know, into building kind of the right kind of workflows that take in kind of, for example, the data and try to answer kind of directly that those problems that, you know, the chemists and the biologists are asking, and then also kind of building the infrastructure. And so this to say that, you know, even with models fully open. You know, we see a ton of potential for, you know, products in the space and the critical part about a product is that even, you know, for example, with an open source model, you know, running the model is not free, you know, as we were saying, these are pretty expensive model and especially, and maybe we‚Äôll get into this, you know, these days we‚Äôre seeing kind of pretty dramatic inference time scaling of these models where, you know, the more you run them, the better the results are. But there, you know, you see. You start getting into a point that compute and compute costs becomes a critical factor. And so putting a lot of work into building the right kind of infrastructure, building the optimizations and so on really allows us to provide, you know, a much better service potentially to the open source models. That to say, you know, even though, you know, with a product, we can provide a much better service. I do still think, and we will continue to put a lot of our models open source because the critical kind of role. I think of open source. Models is, you know, helping kind of the community progress on the research and, you know, from which we, we all benefit. And so, you know, we‚Äôll continue to on the one hand, you know, put some of our kind of base models open source so that the field can, can be on top of it. And, you know, as we discussed earlier, we learn a ton from, you know, the way that the field uses and builds on top of our models, but then, you know, try to build a product that gives the best experience possible to scientists. So that, you know, like a chemist or a biologist doesn‚Äôt need to, you know, spin off a GPU and, you know, set up, you know, our open source model in a particular way, but can just, you know, a bit like, you know, I, even though I am a computer scientist, machine learning scientist, I don‚Äôt necessarily, you know, take a open source LLM and try to kind of spin it off. But, you know, I just maybe open a GPT app or a cloud code and just use it as an amazing product. We kind of want to give the same experience. So this front world.

**Brandon** [00:40:40]: I heard a good analogy yesterday that a surgeon doesn‚Äôt want the hospital to design a scalpel, right?

**Brandon** [00:40:48]: So just buy the scalpel.

**RJ** [00:40:50]: You wouldn‚Äôt believe like the number of people, even like in my short time, you know, between AlphaFold3 coming out and the end of the PhD, like the number of people that would like reach out just for like us to like run AlphaFold3 for them, you know, or things like that. Just because like, you know, bolts in our case, you know, just because it‚Äôs like. It‚Äôs like not that easy, you know, to do that, you know, if you‚Äôre not a computational person. And I think like part of the goal here is also that, you know, we continue to obviously build the interface with computational folks, but that, you know, the models are also accessible to like a larger, broader audience. And then that comes from like, you know, good interfaces and stuff like that.

**Gabriel** [00:41:27]: I think one like really interesting thing about bolts is that with the release of it, you didn‚Äôt just release a model, but you created a community. Yeah. Did that community, it grew very quickly. Did that surprise you? And like, what is the evolution of that community and how is that fed into bolts?

**RJ** [00:41:43]: If you look at its growth, it‚Äôs like very much like when we release a new model, it‚Äôs like, there‚Äôs a big, big jump, but yeah, it‚Äôs, I mean, it‚Äôs been great. You know, we have a Slack community that has like thousands of people on it. And it‚Äôs actually like self-sustaining now, which is like the really nice part because, you know, it‚Äôs, it‚Äôs almost overwhelming, I think, you know, to be able to like answer everyone‚Äôs questions and help. It‚Äôs really difficult, you know. The, the few people that we were, but it ended up that like, you know, people would answer each other‚Äôs questions and like, sort of like, you know, help one another. And so the Slack, you know, has been like kind of, yeah, self, self-sustaining and that‚Äôs been, it‚Äôs been really cool to see.

**RJ** [00:42:21]: And, you know, that‚Äôs, that‚Äôs for like the Slack part, but then also obviously on GitHub as well. We‚Äôve had like a nice, nice community. You know, I think we also aspire to be even more active on it, you know, than we‚Äôve been in the past six months, which has been like a bit challenging, you know, for us. But. Yeah, the community has been, has been really great and, you know, there‚Äôs a lot of papers also that have come out with like new evolutions on top of bolts and it‚Äôs surprised us to some degree because like there‚Äôs a lot of models out there. And I think like, you know, sort of people converging on that was, was really cool. And, you know, I think it speaks also, I think, to the importance of like, you know, when, when you put code out, like to try to put a lot of emphasis and like making it like as easy to use as possible and something we thought a lot about when we released the code base. You know, it‚Äôs far from perfect, but, you know.

**Brandon** [00:43:07]: Do you think that that was one of the factors that caused your community to grow is just the focus on easy to use, make it accessible? I think so.

**RJ** [00:43:14]: Yeah. And we‚Äôve, we‚Äôve heard it from a few people over the, over the, over the years now. And, you know, and some people still think it should be a lot nicer and they‚Äôre, and they‚Äôre right. And they‚Äôre right. But yeah, I think it was, you know, at the time, maybe a little bit easier than, than other things.

**Gabriel** [00:43:29]: The other thing part, I think led to, to the community and to some extent, I think, you know, like the somewhat the trust in the community. Kind of what we, what we put out is the fact that, you know, it‚Äôs not really been kind of, you know, one model, but, and maybe we‚Äôll talk about it, you know, after Boltz 1, you know, there were maybe another couple of models kind of released, you know, or open source kind of soon after. We kind of continued kind of that open source journey or at least Boltz 2, where we are not only improving kind of structure prediction, but also starting to do affinity predictions, understanding kind of the strength of the interactions between these different models, which is this critical component. critical property that you often want to optimize in discovery programs. And then, you know, more recently also kind of protein design model. And so we‚Äôve sort of been building this suite of, of models that come together, interact with one another, where, you know, kind of, there is almost an expectation that, you know, we, we take very at heart of, you know, always having kind of, you know, across kind of the entire suite of different tasks, the best or across the best. model out there so that it‚Äôs sort of like our open source tool can be kind of the go-to model for everybody in the, in the industry. I really want to talk about Boltz 2, but before that, one last question in this direction, was there anything about the community which surprised you? Were there any, like, someone was doing something and you‚Äôre like, why would you do that? That‚Äôs crazy. Or that‚Äôs actually genius. And I never would have thought about that.

**RJ** [00:45:01]: I mean, we‚Äôve had many contributions. I think like some of the. Interesting ones, like, I mean, we had, you know, this one individual who like wrote like a complex GPU kernel, you know, for part of the architecture on a piece of, the funny thing is like that piece of the architecture had been there since AlphaFold 2, and I don‚Äôt know why it took Boltz for this, you know, for this person to, you know, to decide to do it, but that was like a really great contribution. We‚Äôve had a bunch of others, like, you know, people figuring out like ways to, you know, hack the model to do something. They click peptides, like, you know, there‚Äôs, I don‚Äôt know if there‚Äôs any other interesting ones come to mind.

**Gabriel** [00:45:41]: One cool one, and this was, you know, something that initially was proposed as, you know, as a message in the Slack channel by Tim O‚ÄôDonnell was basically, he was, you know, there are some cases, especially, for example, we discussed, you know, antibody-antigen interactions where the models don‚Äôt necessarily kind of get the right answer. What he noticed is that, you know, the models were somewhat stuck into predicting kind of the antibodies. And so he basically ran the experiments in this model, you can condition, basically, you can give hints. And so he basically gave, you know, random hints to the model, basically, okay, you should bind to this residue, you should bind to the first residue, or you should bind to the 11th residue, or you should bind to the 21st residue, you know, basically every 10 residues scanning the entire antigen.

**Brandon** [00:46:33]: Residues are the...

**Gabriel** [00:46:34]: The amino acids. The amino acids, yeah. So the first amino acids. The 11 amino acids, and so on. So it‚Äôs sort of like doing a scan, and then, you know, conditioning the model to predict all of them, and then looking at the confidence of the model in each of those cases and taking the top. And so it‚Äôs sort of like a very somewhat crude way of doing kind of inference time search. But surprisingly, you know, for antibody-antigen prediction, it actually kind of helped quite a bit. And so there‚Äôs some, you know, interesting ideas that, you know, obviously, as kind of developing the model, you say kind of, you know, wow. This is why would the model, you know, be so dumb. But, you know, it‚Äôs very interesting. And that, you know, leads you to also kind of, you know, start thinking about, okay, how do I, can I do this, you know, not with this brute force, but, you know, in a smarter way.

**RJ** [00:47:22]: And so we‚Äôve also done a lot of work on that direction. And that speaks to, like, the, you know, the power of scoring. We‚Äôre seeing that a lot. I‚Äôm sure we‚Äôll talk about it more when we talk about BullsGen. But, you know, our ability to, like, take a structure and determine that that structure is, like... Good. You know, like, somewhat accurate. Whether that‚Äôs a single chain or, like, an interaction is a really powerful way of improving, you know, the models. Like, sort of like, you know, if you can sample a ton and you assume that, like, you know, if you sample enough, you‚Äôre likely to have, like, you know, the good structure. Then it really just becomes a ranking problem. And, you know, now we‚Äôre, you know, part of the inference time scaling that Gabby was talking about is very much that. It‚Äôs like, you know, the more we sample, the more we, like, you know, the ranking model. The ranking model ends up finding something it really likes. And so I think our ability to get better at ranking, I think, is also what‚Äôs going to enable sort of the next, you know, next big, big breakthroughs. Interesting.

**Brandon** [00:48:17]: But I guess there‚Äôs a, my understanding, there‚Äôs a diffusion model and you generate some stuff and then you, I guess, it‚Äôs just what you said, right? Then you rank it using a score and then you finally... And so, like, can you talk about those different parts? Yeah.

**Gabriel** [00:48:34]: So, first of all, like, the... One of the critical kind of, you know, beliefs that we had, you know, also when we started working on Boltz 1 was sort of like the structure prediction models are somewhat, you know, our field version of some foundation models, you know, learning about kind of how proteins and other molecules interact. And then we can leverage that learning to do all sorts of other things. And so with Boltz 2, we leverage that learning to do affinity predictions. So understanding kind of, you know, if I give you this protein, this molecule. How tightly is that interaction? For Boltz 1, what we did was taking kind of that kind of foundation models and then fine tune it to predict kind of entire new proteins. And so the way basically that that works is sort of like instead of for the protein that you‚Äôre designing, instead of fitting in an actual sequence, you fit in a set of blank tokens. And you train the models to, you know, predict both the structure of kind of that protein. The structure also, what the different amino acids of that proteins are. And so basically the way that Boltz 1 operates is that you feed a target protein that you may want to kind of bind to or, you know, another DNA, RNA. And then you feed the high level kind of design specification of, you know, what you want your new protein to be. For example, it could be like an antibody with a particular framework. It could be a peptide. It could be many other things. And that‚Äôs with natural language or? And that‚Äôs, you know, basically, you know, prompting. And we have kind of this sort of like spec that you specify. And, you know, you feed kind of this spec to the model. And then the model translates this into, you know, a set of, you know, tokens, a set of conditioning to the model, a set of, you know, blank tokens. And then, you know, basically the codes as part of the diffusion models, the codes. It‚Äôs a new structure and a new sequence for your protein. And, you know, basically, then we take that. And as Jeremy was saying, we are trying to score it and, you know, how good of a binder it is to that original target.

**Brandon** [00:50:51]: You‚Äôre using basically Boltz to predict the folding and the affinity to that molecule. So and then that kind of gives you a score? Exactly.

**Gabriel** [00:51:03]: So you use this model to predict the folding. And then you do two things. One is that you predict the structure and with something like Boltz2, and then you basically compare that structure with what the model predicted, what Boltz2 predicted. And this is sort of like in the field called consistency. It‚Äôs basically you want to make sure that, you know, the structure that you‚Äôre predicting is actually what you‚Äôre trying to design. And that gives you a much better confidence that, you know, that‚Äôs a good design. And so that‚Äôs the first filtering. And the second filtering that we did as part of kind of the Boltz2 pipeline that was released is that we look at the confidence that the model has in the structure. Now, unfortunately, kind of going to your question of, you know, predicting affinity, unfortunately, confidence is not a very good predictor of affinity. And so one of the things that we‚Äôve actually done a ton of progress, you know, since we released Boltz2.

**Brandon** [00:52:03]: And kind of we have some new results that we are going to kind of announce soon is kind of, you know, the ability to get much better hit rates when instead of, you know, trying to rely on confidence of the model, we are actually directly trying to predict the affinity of that interaction. Okay. Just backing up a minute. So your diffusion model actually predicts not only the protein sequence, but also the folding of it. Exactly.

**Gabriel** [00:52:32]: And actually, you can... One of the big different things that we did compared to other models in the space, and, you know, there were some papers that had already kind of done this before, but we really scaled it up was, you know, basically somewhat merging kind of the structure prediction and the sequence prediction into almost the same task. And so the way that Boltz2 works is that you are basically the only thing that you‚Äôre doing is predicting the structure. So the only sort of... Supervision is we give you a supervision on the structure, but because the structure is atomic and, you know, the different amino acids have a different atomic composition, basically from the way that you place the atoms, we also understand not only kind of the structure that you wanted, but also the identity of the amino acid that, you know, the models believed was there. And so we‚Äôve basically, instead of, you know, having these two supervision signals, you know, one discrete, one continuous. That somewhat, you know, don‚Äôt interact well together. We sort of like build kind of like an encoding of, you know, sequences in structures that allows us to basically use exactly the same supervision signal that we were using to Boltz2 that, you know, you know, largely similar to what AlphaVol3 proposed, which is very scalable. And we can use that to design new proteins. Oh, interesting.

**RJ** [00:53:58]: Maybe a quick shout out to Hannes Stark on our team who like did all this work. Yeah.

**Gabriel** [00:54:04]: Yeah, that was a really cool idea. I mean, like looking at the paper and there‚Äôs this is like encoding or you just add a bunch of, I guess, kind of atoms, which can be anything, and then they get sort of rearranged and then basically plopped on top of each other so that and then that encodes what the amino acid is. And there‚Äôs sort of like a unique way of doing this. It was that was like such a really such a cool, fun idea.

**RJ** [00:54:29]: I think that idea was had existed before. Yeah, there were a couple of papers.

**Gabriel** [00:54:33]: Yeah, I had proposed this and and Hannes really took it to the large scale.

**Brandon** [00:54:39]: In the paper, a lot of the paper for Boltz2Gen is dedicated to actually the validation of the model. In my opinion, all the people we basically talk about feel that this sort of like in the wet lab or whatever the appropriate, you know, sort of like in real world validation is the whole problem or not the whole problem, but a big giant part of the problem. So can you talk a little bit about the highlights? From there, that really because to me, the results are impressive, both from the perspective of the, you know, the model and also just the effort that went into the validation by a large team.

**Gabriel** [00:55:18]: First of all, I think I should start saying is that both when we were at MIT and Thomas Yacolas and Regina Barzillai‚Äôs lab, as well as at Boltz, you know, we are not a we‚Äôre not a biolab and, you know, we are not a therapeutic company. And so to some extent, you know, we were first forced to, you know, look outside of, you know, our group, our team to do the experimental validation. One of the things that really, Hannes, in the team pioneer was the idea, OK, can we go not only to, you know, maybe a specific group and, you know, trying to find a specific system and, you know, maybe overfit a bit to that system and trying to validate. But how can we test this model? So. Across a very wide variety of different settings so that, you know, anyone in the field and, you know, printing design is, you know, such a kind of wide task with all sorts of different applications from therapeutic to, you know, biosensors and many others that, you know, so can we get a validation that is kind of goes across many different tasks? And so he basically put together, you know, I think it was something like, you know, 25 different. You know, academic and industry labs that committed to, you know, testing some of the designs from the model and some of this testing is still ongoing and, you know, giving results kind of back to us in exchange for, you know, hopefully getting some, you know, new great sequences for their task. And he was able to, you know, coordinate this, you know, very wide set of, you know, scientists and already in the paper, I think we. Shared results from, I think, eight to 10 different labs kind of showing results from, you know, designing peptides, designing to target, you know, ordered proteins, peptides targeting disordered proteins, which are results, you know, of designing proteins that bind to small molecules, which are results of, you know, designing nanobodies and across a wide variety of different targets. And so that‚Äôs sort of like. That gave to the paper a lot of, you know, validation to the model, a lot of validation that was kind of wide.

**Brandon** [00:57:39]: And so those would be therapeutics for those animals or are they relevant to humans as well? They‚Äôre relevant to humans as well.

**Gabriel** [00:57:45]: Obviously, you need to do some work into, quote unquote, humanizing them, making sure that, you know, they have the right characteristics to so they‚Äôre not toxic to humans and so on.

**RJ** [00:57:57]: There are some approved medicine in the market that are nanobodies. There‚Äôs a general. General pattern, I think, in like in trying to design things that are smaller, you know, like it‚Äôs easier to manufacture at the same time, like that comes with like potentially other challenges, like maybe a little bit less selectivity than like if you have something that has like more hands, you know, but the yeah, there‚Äôs this big desire to, you know, try to design many proteins, nanobodies, small peptides, you know, that just are just great drug modalities.

**Brandon** [00:58:27]: Okay. I think we were left off. We were talking about validation. Validation in the lab. And I was very excited about seeing like all the diverse validations that you‚Äôve done. Can you go into some more detail about them? Yeah. Specific ones. Yeah.

**RJ** [00:58:43]: The nanobody one. I think we did. What was it? 15 targets. Is that correct? 14. 14 targets. Testing. So we typically the way this works is like we make a lot of designs. All right. On the order of like tens of thousands. And then we like rank them and we pick like the top. And in this case, and was 15 right for each target and then we like measure sort of like the success rates, both like how many targets we were able to get a binder for and then also like more generally, like out of all of the binders that we designed, how many actually proved to be good binders. Some of the other ones I think involved like, yeah, like we had a cool one where there was a small molecule or design a protein that binds to it. That has a lot of like interesting applications, you know, for example. Like Gabri mentioned, like biosensing and things like that, which is pretty cool. We had a disordered protein, I think you mentioned also. And yeah, I think some of those were some of the highlights. Yeah.

**Gabriel** [00:59:44]: So I would say that the way that we structure kind of some of those validations was on the one end, we have validations across a whole set of different problems that, you know, the biologists that we were working with came to us with. So we were trying to. For example, in some of the experiments, design peptides that would target the RACC, which is a target that is involved in metabolism. And we had, you know, a number of other applications where we were trying to design, you know, peptides or other modalities against some other therapeutic relevant targets. We designed some proteins to bind small molecules. And then some of the other testing that we did was really trying to get like a more broader sense. So how does the model work, especially when tested, you know, on somewhat generalization? So one of the things that, you know, we found with the field was that a lot of the validation, especially outside of the validation that was on specific problems, was done on targets that have a lot of, you know, known interactions in the training data. And so it‚Äôs always a bit hard to understand, you know, how much are these models really just regurgitating kind of what they‚Äôve seen or trying to imitate. What they‚Äôve seen in the training data versus, you know, really be able to design new proteins. And so one of the experiments that we did was to take nine targets from the PDB, filtering to things where there is no known interaction in the PDB. So basically the model has never seen kind of this particular protein bound or a similar protein bound to another protein. So there is no way that. The model from its training set can sort of like say, okay, I‚Äôm just going to kind of tweak something and just imitate this particular kind of interaction. And so we took those nine proteins. We worked with adaptive CRO and basically tested, you know, 15 mini proteins and 15 nanobodies against each one of them. And the very cool thing that we saw was that on two thirds of those targets, we were able to, from this 15 design, get nanomolar binders, nanomolar, roughly speaking, just a measure of, you know, how strongly kind of the interaction is, roughly speaking, kind of like a nanomolar binder is approximately the kind of binding strength or binding that you need for a therapeutic. Yeah. So maybe switching directions a bit. Bolt‚Äôs lab was just announced this week or was it last week? Yeah. This is like your. First, I guess, product, if that‚Äôs if you want to call it that. Can you talk about what Bolt‚Äôs lab is and yeah, you know, what you hope that people take away from this? Yeah.

**RJ** [01:02:44]: You know, as we mentioned, like I think at the very beginning is the goal with the product has been to, you know, address what the models don‚Äôt on their own. And there‚Äôs largely sort of two categories there. I‚Äôll split it in three. The first one. It‚Äôs one thing to predict, you know, a single interaction, for example, like a single structure. It‚Äôs another to like, you know, very effectively search a space, a design space to produce something of value. What we found, like sort of building on this product is that there‚Äôs a lot of steps involved, you know, in that there‚Äôs certainly need to like, you know, accompany the user through, you know, one of those steps, for example, is like, you know, the creation of the target itself. You know, how do we make sure that the model has like a good enough understanding of the target? So we can like design something and there‚Äôs all sorts of tricks, you know, that you can do to improve like a particular, you know, structure prediction. And so that‚Äôs sort of like, you know, the first stage. And then there‚Äôs like this stage of like, you know, designing and searching the space efficiently. You know, for something like BullsGen, for example, like you, you know, you design many things and then you rank them, for example, for small molecule process, a little bit more complicated. We actually need to also make sure that the molecules are synthesizable. And so the way we do that is that, you know, we have a generative model that learns. To use like appropriate building blocks such that, you know, it can design within a space that we know is like synthesizable. And so there‚Äôs like, you know, this whole pipeline really of different models involved in being able to design a molecule. And so that‚Äôs been sort of like the first thing we call them agents. We have a protein agent and we have a small molecule design agents. And that‚Äôs really like at the core of like what powers, you know, the BullsLab platform.

**Brandon** [01:04:22]: So these agents, are they like a language model wrapper or they‚Äôre just like your models and you‚Äôre just calling them agents? A lot. Yeah. Because they, they, they sort of perform a function on behalf of.

**RJ** [01:04:33]: They‚Äôre more of like a, you know, a recipe, if you wish. And I think we use that term sort of because of, you know, sort of the complex pipelining and automation, you know, that goes into like all this plumbing. So that‚Äôs the first part of the product. The second part is the infrastructure. You know, we need to be able to do this at very large scale for any one, you know, group that‚Äôs doing a design campaign. Let‚Äôs say you‚Äôre designing, you know, I‚Äôd say a hundred thousand possible candidates. Right. To find the good one that is, you know, a very large amount of compute, you know, for small molecules, it‚Äôs on the order of like a few seconds per designs for proteins can be a bit longer. And so, you know, ideally you want to do that in parallel, otherwise it‚Äôs going to take you weeks. And so, you know, we‚Äôve put a lot of effort into like, you know, our ability to have a GPU fleet that allows any one user, you know, to be able to do this kind of like large parallel search.

**Brandon** [01:05:23]: So you‚Äôre amortizing the cost over your users. Exactly. Exactly.

**RJ** [01:05:27]: And, you know, to some degree, like it‚Äôs whether you. Use 10,000 GPUs for like, you know, a minute is the same cost as using, you know, one GPUs for God knows how long. Right. So you might as well try to parallelize if you can. So, you know, a lot of work has gone, has gone into that, making it very robust, you know, so that we can have like a lot of people on the platform doing that at the same time. And the third one is, is the interface and the interface comes in, in two shapes. One is in form of an API and that‚Äôs, you know, really suited for companies that want to integrate, you know, these pipelines, these agents.

**RJ** [01:06:01]: So we‚Äôre already partnering with, you know, a few distributors, you know, that are gonna integrate our API. And then the second part is the user interface. And, you know, we, we‚Äôve put a lot of thoughts also into that. And this is when I, I mentioned earlier, you know, this idea of like broadening the audience. That‚Äôs kind of what the, the user interface is about. And we‚Äôve built a lot of interesting features in it, you know, for example, for collaboration, you know, when you have like potentially multiple medicinal chemists or. We‚Äôre going through the results and trying to pick out, okay, like what are the molecules that we‚Äôre going to go and test in the lab? It‚Äôs powerful for them to be able to, you know, for example, each provide their own ranking and then do consensus building. And so there‚Äôs a lot of features around launching these large jobs, but also around like collaborating on analyzing the results that we try to solve, you know, with that part of the platform. So Bolt‚Äôs lab is sort of a combination of these three objectives into like one, you know, sort of cohesive platform. Who is this accessible to? Everyone. You do need to request access today. We‚Äôre still like, you know, sort of ramping up the usage, but anyone can request access. If you are an academic in particular, we, you know, we provide a fair amount of free credit so you can play with the platform. If you are a startup or biotech, you may also, you know, reach out and we‚Äôll typically like actually hop on a call just to like understand what you‚Äôre trying to do and also provide a lot of free credit to get started. And of course, also with larger companies, we can deploy this platform in a more like secure environment. And so that‚Äôs like more like customizing. You know, deals that we make, you know, with the partners, you know, and that‚Äôs sort of the ethos of Bolt. I think this idea of like servicing everyone and not necessarily like going after just, you know, the really large enterprises. And that starts from the open source, but it‚Äôs also, you know, a key design principle of the product itself.

**Gabriel** [01:07:48]: One thing I was thinking about with regards to infrastructure, like in the LLM space, you know, the cost of a token has gone down by I think a factor of a thousand or so over the last three years, right? Yeah. And is it possible that like essentially you can exploit economies of scale and infrastructure that you can make it cheaper to run these things yourself than for any person to roll their own system? A hundred percent. Yeah.

**RJ** [01:08:08]: I mean, we‚Äôre already there, you know, like running Bolts on our platform, especially on a large screen is like considerably cheaper than it would probably take anyone to put the open source model out there and run it. And on top of the infrastructure, like one of the things that we‚Äôve been working on is accelerating the models. So, you know. Our small molecule screening pipeline is 10x faster on Bolts Lab than it is in the open source, you know, and that‚Äôs also part of like, you know, building a product, you know, of something that scales really well. And we really wanted to get to a point where like, you know, we could keep prices very low in a way that it would be a no-brainer, you know, to use Bolts through our platform.

**Gabriel** [01:08:52]: How do you think about validation of your like agentic systems? Because, you know, as you were saying earlier. Like we‚Äôre AlphaFold style models are really good at, let‚Äôs say, monomeric, you know, proteins where you have, you know, co-evolution data. But now suddenly the whole point of this is to design something which doesn‚Äôt have, you know, co-evolution data, something which is really novel. So now you‚Äôre basically leaving the domain that you thought was, you know, that you know you are good at. So like, how do you validate that?

**RJ** [01:09:22]: Yeah, I like every complete, but there‚Äôs obviously, you know, a ton of computational metrics. That we rely on, but those are only take you so far. You really got to go to the lab, you know, and test, you know, okay, with this method A and this method B, how much better are we? You know, how much better is my, my hit rate? How stronger are my binders? Also, it‚Äôs not just about hit rate. It‚Äôs also about how good the binders are. And there‚Äôs really like no way, nowhere around that. I think we‚Äôre, you know, we‚Äôve really ramped up the amount of experimental validation that we do so that we like really track progress, you know, as scientifically sound, you know. Yeah. As, as possible out of this, I think.

**Gabriel** [01:10:00]: Yeah, no, I think, you know, one thing that is unique about us and maybe companies like us is that because we‚Äôre not working on like maybe a couple of therapeutic pipelines where, you know, our validation would be focused on those. We, when we do an experimental validation, we try to test it across tens of targets. And so that on the one end, we can get a much more statistically significant result and, and really allows us to make progress. From the methodological side without being, you know, steered by, you know, overfitting on any one particular system. And of course we choose, you know, we always try to choose targets and problems are sort of like at the frontier of what‚Äôs possible today. So, you know, you don‚Äôt want something too easy. You don‚Äôt want something too hard. Otherwise you‚Äôre not going to see progress. And so, you know, this is a somewhat evolving set of targets. We talked earlier about the targets that we looked at with, with Boltchan. And now we are even trying kind of, you know, even harder targets, both for small molecule and proteins. And so we try to keep ourselves on the, on the boundary of what‚Äôs possible. So do you have like infrastructure or is this is like, you just have a lot of different partnerships with academic labs and you‚Äôre just kind of keep pushing on these and driving these. We do partially this through academic labs more and more. We do this through CROs just because of, you know, to some extent is also, we need kind of replicability often kind of, you know, going after the same time. So we try to, we try to keep our, our targets, you know, multiple times and, you know, to see the, the progress from, you know, one month to the next. And speed. And speed. And speed. Speed of execution. Yeah. And, So what happens if you start getting a bunch of like really strong biters against therapeutic targets? What do you do?

**RJ** [01:11:43]: Release them. Yeah.

**Gabriel** [01:11:45]: But you can release them in open source? Like,

**RJ** [01:11:47]: Yeah, I mean, you know, I mean, when we say we have no interest in making dress, we‚Äôre serious. Like, you know, uh, I mean, when it, when it was with the academic labs, basically the, you know, I was, they keep it, they do a lot of it.

**Gabriel** [01:12:02]: I will also say, and I think this has been a bit of the issue that I have with some of the things that have been said in the field, is when we say that we design new proteins or we say that we design new molecules, go and bind these particular targets. We should be very clear, these are not drugs. These are not things that are ready to be put into a human. And there is still a lot of development that goes with it. And so this is kind of to us, we see ourselves as building tools for scientists. At the end of the day, it really relies on the scientist having a great therapeutic hypothesis and then pushing through kind of all the stages of development. And, you know, we try to build tools that can accompany them in that journey. It‚Äôs not like a magic box where, you know, you can just turn it and get FDA approved drugs.

**Brandon** [01:13:06]: But actually, that brings up an interesting question that I‚Äôve been wondering about is, do you guys see yourself staying in this, for lack of a better way of saying it, layer? Or do you think that you‚Äôll start to... Yeah. Either on the physical sense, looking at different layers of the virtual cell, so to speak, or also, you know, so there‚Äôs like the development process that goes, you know, sort of like design preclinical, clinical approval and thinking about improving the performance throughout that process based on the designs. Is that a direction that you guys are pushing? Yeah.

**Gabriel** [01:13:45]: So one of the things, as Jeremy said, you know, we are... We are not a therapeutic company. We want to kind of stay not to be a therapeutic company, always be at the service of, you know, all the different, you know, companies, including therapeutic companies that we serve. And, you know, that to some extent does mean, you know, that we need to try to, you know, go deeper and deeper in getting these models better and better. One of the things that we are doing across, you know, many other in the field is, you know, now that we are really... They‚Äôre starting to be good, both for small molecule and... For proteins to design kind of binders, design relatively tight binders, is starting to look at all these other properties, you know, they‚Äôre called developpabilities or at me that, you know, we care about when developing a drug and try, can we design them from, from Gageco. The thing about those properties in some of them, you know, you need to, you know, start having an understanding of the cell. And so that‚Äôs on the one hand, kind of why we need that understanding. But also, you know, the way... The way that we also think about all different and complex diseases is that these models, then these tools that we‚Äôre building have a good understanding of kind of, you know, biomolecular interactions and kind of their interactions. Now, at the same time, every disease is often kind of unique and every therapeutic hypothesis is unique. And so you maybe want to have something that needs to hit the particular, you know, let‚Äôs say target in a virus in a particular way, but you don‚Äôt maybe know exactly. So you can start to have a more open-minded understanding of what‚Äôs, what‚Äôs a way you want to do. And so maybe in the first set of designs, you‚Äôre going to try to target different epitopes in different ways, and then you‚Äôre going to test them in the lab, maybe directly in vivo, and you‚Äôre going to see which ones work and which ones don‚Äôt. And so then you need to bring those results back into the models. And then the models can start to have a more wider understanding, you know, not just of the biophysical of the antibodies interacting with that target, but also how that is shaped within the cell. And so first of all, you know, that means on the one end that we need, you know, kind of these loops, and this is also partially how we, we designed the platform to be. But that also means that we also need to start understanding more and more kind of higher level things. And, you know, I wouldn‚Äôt say that we‚Äôre working in any way on like a virtual cell like others are, but we‚Äôre definitely thinking kind of very deeply about kind of, you know, how does, you know, kind of the way that we target certain proteins. Interfere, interact with, you know, maybe pathways that are existing in the cell. One question that has come up is you talk a lot about user interface and so on. And I think this is really important, but like my experience with dealing with medicinal chemists, when you get the machine learning models, is they are the most superstitious, skeptical, like pseudo-religious people I‚Äôve ever talked to when it comes to doing science. Sorry for the medicinal chemists listening. Yeah, they‚Äôre amazing. Like, they‚Äôre absolutely, I‚Äôve worked with some spectacular medicinal chemists who just pull magic out of their hat again and again, and I have no idea how they do it. But when you bring them a machine learning model, it is sometimes quite tricky to get them to deal with it. How has your interaction been with this? And how have you thought about, like, building Bolt‚Äôs lab to work with the skeptics? One of the great value unlocks for us and for our product has been when we brought to the team a medicinal chemist. His name is Jeffrey. So I think kind of like on the one hand, you know, day one, you know, he obviously had a lot of opinions on kind of a lot of the ways that we should change, you know, both kind of the way that the agents worked, the way that the platform worked. But it‚Äôs been really amazing kind of, you know, once also we started kind of shaping kind of the platform in a better way with this feedback, how we went from, you know, to some extent, you know, a fair skepticism to him, you know, actually using, you know, a lot of the things that we did. Yeah. So he‚Äôs doing a lot more compute than any of our computational folks in the team, you know, at times that, you know, he‚Äôs, you know, running, you know, he has all these sort of hypotheses. Okay, maybe I can hit this protein this particular way. I can hit in that way. Actually, let me look at for this particular molecular space. Let me try to optimize for this particular interactions. So he ends up, you know, running several screens in parallel, you know, using hundreds of GPUs, you know, on his own. And, you know, so this has been, you know, pretty incredible to see kind of how, you know, maybe the way that I was more thinking about a problem, which is, okay, you‚Äôre just trying to design a binder, a small molecule to a particular protein. The way that he thinks about it is, you know, much more deeply and, you know, trying all these different things, these different hypotheses. And then, you know, once he gets the results from the model, he doesn‚Äôt just, you know, take the top 15, but he really kind of looks over and, you know, kind of tries to understand, you know, the different things. And then when we select, you know, maybe some designs to bring forth, you know, he has, you know, something where, you know, both the models understand that something‚Äôs good, but himself as well. And that‚Äôs why we also built kind of the platform to be an interface for, you know, this kind of chemist and, you know, also like engineers. Yeah. Collaborative experience.

**RJ** [01:19:09]: I think at the end of the day, like, you know, for people to be convinced, you have to show them something that they didn‚Äôt think was possible. And until you have that aha moment, you know, I think the skepticism will remain. But then when, you know, every once in a while, I think there‚Äôs like a result that like really surprises people. And then it‚Äôs like, oh, wow, okay, this is actually, I can do something with this. So you just get in their hands, have them try it out, and they‚Äôll be convinced. Yeah, or like maybe once the lab results come back. Or their friends. Yeah, or maybe one of their colleagues is convinced. Yeah. I think it takes going to the lab at some point. There‚Äôs no avoiding that, you know, as beautiful as the platform can be, as nice as the molecules might look, you know, that the model predicted. I think what really convinces people is like, you know, hits. Yeah.

**Gabriel** [01:19:54]: Yeah. You see the results. Exactly. Yeah. Cool. Thank you for, you know, taking the time to chat with us. Yeah. You know, is there anything that you would like your audience to know? I mean, first of all, you know, we‚Äôre just getting started, you know, continuing to build a team. And so definitely always looking for great folks, both on the kind of, you know, software side, you know, machine learning side, but also scientists to join the team and help us, you know, shape. On the infrastructure side, too. Indeed. If you think that if you want a new challenge, because this is not just next token prediction, this is really a new engineering challenge. Exactly. Yeah. If you, if no matter, you know, how much experience you have with, you know, biologists and chemistry, if you want to come, you know, help us in a shape, what, you know, biology and chemistry, hopefully we‚Äôll look like in five, 10 years. We‚Äôd love to hear from you. And so go to boltz.bio and, you know, come join the team. Cool. Thank you. Awesome. Thank you so much. Thank you.

---

## Key Takeaways

### Notable Quotes

> the next frontier lies in modeling complex interactions and generative protein design

*Context: Discussing the evolution of structural biology models and Boltz's focus.*

> Boltz-1 was moving from regression to a generative diffusion approach

*Context: Explaining the shift in model architecture from static prediction to generative models.*

> Boltz Lab platform provides 'agents' for protein and small molecule design

*Context: Introducing the Boltz Lab infrastructure for faster and more efficient drug design.*

## Related Topics

- [[topics/generative-protein-design]]
- [[topics/open-source]]
- [[topics/structural-biology]]
- [[topics/drug-discovery]]

---

## Related Articles

<CardGroup cols={1}>
  <Card
    title="Owning the AI Pareto Frontier ‚Äî Jeff Dean"
    icon="newspaper"
    href="/kb/articles/owning-the-ai-pareto-frontier-jeff-dean-b9a15207"
  >
    Swyx ¬∑ explanation ¬∑ 69% similar
  </Card>
  <Card
    title="The First Mechanistic Interpretability Frontier Lab ‚Äî Myra Deng & Mark Bissell of Goodfire AI"
    icon="newspaper"
    href="/kb/articles/the-first-mechanistic-interpretability-frontier-lab-myra-den-7ed14561"
  >
    Swyx ¬∑ explanation ¬∑ 68% similar
  </Card>
  <Card
    title="The Scientist and the Simulator"
    icon="newspaper"
    href="/kb/articles/the-scientist-and-the-simulator-41a159da"
  >
    Swyx ¬∑ explanation ¬∑ 64% similar
  </Card>
</CardGroup>

---

<Note>
Originally published at [https://www.latent.space/p/boltz](https://www.latent.space/p/boltz).
</Note>
